---

---

symbols : TAK   

save search

---

Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs
Published: 2024-04-22 (Crawled : 09:00) - prnewswire.com
SMFNF | News | $55.76 -0.13% -1.2% 0 |

Finance

| -0.13% | O: -0.16% H: 3.14% C: 0.04%
ALPMY | News | $9.53 0.32% -1.11% 0 |

Manufacturing

| 0.32% | O: 0.63% H: 0.0% C: -0.31%
TAK | News | $13.36 0.91% 0.0% 1.5M |

Health Technology

| 1.17% | O: 0.8% H: 0.75% C: 0.38%
drug company for agreement

---

Progressive Familial Intrahepatic Cholestasis Treatment Market Projected to Reach $156.14 million by 2030 - Exclusive Report by 360iResearch
Published: 2024-04-19 (Crawled : 02:00) - prnewswire.com
TAK | News | $13.36 0.91% 0.0% 1.5M |

Health Technology

| 1.6% | O: 0.42% H: 0.0% C: 0.0%
SNY | News | $47.15 1.84% 1.75% 2M |

Health Technology

| 1.68% | O: 0.82% H: 0.0% C: 0.0%
MIRM | $24.17 1.51% 1.49% 250K |

Health Technology

| 2.55% | O: -0.68% H: 2.52% C: 1.71%
report million reach treatment market

---

U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
Published: 2024-04-18 (Crawled : 23:00) - biospace.com/
TAK | News | $13.36 0.91% 0.0% 1.5M |

Health Technology

| 1.6% | O: 0.0% H: 0.0% C: 0.0%
entyvio fda disease active for therapy

---

Neurvati Neurosciences Announces Appointment of Deborah Dunsire, MD, as Member and Chair of Company Board of Directors
Published: 2024-04-15 (Crawled : 12:00) - prnewswire.com
TAK | News | $13.36 0.91% 0.0% 1.5M |

Health Technology

| -0.82% | O: -1.19% H: 0.26% C: -0.98%
company

---

Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
Published: 2024-03-26 (Crawled : 18:00) - biospace.com/
TAK | News | $13.36 0.91% 0.0% 1.5M |

Health Technology

| -5.58% | O: 1.84% H: 0.24% C: -0.14%
adzynma japan takeda approval injection

---

CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
Published: 2024-03-19 (Crawled : 11:00) - globenewswire.com
TAK | News | $13.36 0.91% 0.0% 1.5M |

Health Technology

| -8.24% | O: -0.07% H: 0.0% C: -0.96%
CNTG | $0.4701 3.12% 3.02% 430K |

Commercial Services

| -32.86% | O: 1.43% H: 1.41% C: -1.41%
partnership genetic takeda disorders

---

Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL
Published: 2024-03-19 (Crawled : 17:00) - biospace.com/
TAK | News | $13.36 0.91% 0.0% 1.5M |

Health Technology

| -8.24% | O: -0.07% H: 0.0% C: -0.96%
iclusig fda drug takeda approval application

---

Monoclonal Antibody (mABs) Therapeutics Market Worth $497.5 billion | MarketsandMarkets™
Published: 2024-03-15 (Crawled : 14:30) - prnewswire.com
TAK | News | $13.36 0.91% 0.0% 1.5M |

Health Technology

| -6.83% | O: 0.21% H: 0.97% C: 0.7%
NVS | News | $95.12 0.81% 5.43% 2.3M |

Health Technology

| -3.42% | O: 0.05% H: 0.14% C: -0.93%
JNJ | News | $149.12 0.82% 0.3% 7.2M |

Health Technology

| -7.26% | O: -1.58% H: 0.0% C: 0.0%
LLY | News | $731.33 0.69% 0.36% 1.7M |

Health Technology

| -3.86% | O: -0.7% H: 0.73% C: -0.16%
ABBV | News | $167.89 0.89% 0.51% 3.6M |

Health Technology

| -6.89% | O: -0.07% H: 0.0% C: 0.0%
SNY | News | $47.15 1.84% 1.75% 2M |

Health Technology

| -4.45% | O: -0.02% H: 0.0% C: 0.0%
REGN | News | $900.16 0.37% 0.32% 240K |

Health Technology

| -6.14% | O: -0.27% H: 1.26% C: 0.84%
AMGN | News | $271.91 1.11% 1.12% 560 |

Health Technology

| 0.14% | O: 0.2% H: 1.14% C: -1.18%
antibody therapeutics market

---

Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia
Published: 2024-03-13 (Crawled : 13:30) - biospace.com/
TAK | News | $13.36 0.91% 0.0% 1.5M |

Health Technology

| -7.03% | O: 0.21% H: 0.17% C: 0.14%
tak-079 positive topline potential results study

---

Alexandria Real Estate Equities, Inc. Announces Significant Early Renewal and 10-Year Lease Extension With Longstanding Credit Tenant Takeda at the Alexandria Center at Kendall Square Mega Campus in Cambridge
Published: 2024-03-04 (Crawled : 12:00) - prnewswire.com
TAK | News | $13.36 0.91% 0.0% 1.5M |

Health Technology

| -8.24% | O: -0.69% H: 0.35% C: 0.14%
ARE | News A | $118.57 2.49% 2.76% 850K |

Finance

| -4.59% | O: -0.01% H: 1.98% C: 1.41%
extension

---

Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas
Published: 2024-02-27 (Crawled : 09:00) - biospace.com/
TAK | News | $13.36 0.91% 0.0% 1.5M |

Health Technology

| -9.79% | O: 0.0% H: 0.47% C: 0.2%
vaccine dengue tak-003 qdenga

---

Non-Small Cell Lung Cancer (NSCLC) Market to Reach $29.95 Billion by 2028, Fueled by Advances in Therapy and Diagnostics
Published: 2024-02-22 (Crawled : 01:00) - prnewswire.com
GLAXF | News | $20.305 0.52% -14.18% 0 |

Health Technology

| -5.41% | O: 0.14% H: 0.0% C: -0.0%
SNYNF | News | $92.7 -2.18% 77 |

Health Technology

| -3.13% | O: 0.26% H: 1.36% C: 1.36%
AZNCF | News | $138.73 1.86% -4.19% 0 |

Health Technology

| 9.24% | O: -0.85% H: 1.12% C: 0.43%
NVSEF | News | $95.11 5.4% 6.88% 490 |

Health Technology

| -6.69% | O: 0.92% H: 0.0% C: 0.0%
UCBJY | $64.93 0.61% -4.38% 6.1K |

Manufacturing

| 27.56% | O: 1.46% H: 0.44% C: 0.44%
ALPMY | News | $9.53 0.32% -1.11% 0 |

Manufacturing

| -14.3% | O: -0.27% H: 0.0% C: -1.17%
TAK | News | $13.36 0.91% 0.0% 1.5M |

Health Technology

| -9.36% | O: -0.2% H: 0.14% C: -0.48%
NVS | News | $95.12 0.81% 5.43% 2.3M |

Health Technology

| -7.6% | O: -0.06% H: 0.46% C: 0.29%
GSK | News | $40.59 2.11% 0.1% 1.3K |

Health Technology

| -3.22% | O: -0.69% H: 1.42% C: 1.22%
LLY | News | $731.33 0.69% 0.36% 1.7M |

Health Technology

| -1.95% | O: 2.37% H: 1.51% C: 0.79%
BMY | $49.14 0.43% 0.2% 6.4M |

Health Technology

| -3.48% | O: -0.65% H: 1.63% C: 1.48%
ABBV | News | $167.89 0.89% 0.51% 3.6M |

Health Technology

| -4.79% | O: -0.88% H: 1.46% C: 1.13%
SNY | News | $47.15 1.84% 1.75% 2M |

Health Technology

| -1.81% | O: 1.67% H: 0.0% C: 0.0%
AZN | News | $70.13 2.31% 2.24% 11K |

Health Technology

| 7.74% | O: -2.81% H: 2.08% C: 1.38%
AMGN | News | $271.91 1.11% 1.12% 560 |

Health Technology

| -4.07% | O: -0.35% H: 1.15% C: 0.96%
lung reach cancer cell diagnostics therapy market

---

Plasma Therapy Global Market Report 2024 - Projected Compound Annual Growth Rate of 12.5%, with Market Set to Reach $0.88 Billion in 2028
Published: 2024-02-22 (Crawled : 01:00) - prnewswire.com
TAK | News | $13.36 0.91% 0.0% 1.5M |

Health Technology

| -9.36% | O: -0.2% H: 0.14% C: -0.48%
BAX | $40.4 2.36% 0.0% 2.7M |

Health Technology

| -4.33% | O: -0.38% H: 0.14% C: -0.14%
KMDA | $5.1 0.99% -0.99% 8K |

Health Technology

| -13.64% | O: 2.0% H: 2.28% C: 1.63%
ADMA 4 | $6.2 -1.12% -1.13% 2M |

Health Technology

| 19.69% | O: 0.19% H: 2.5% C: 1.35%
report reach global set therapy growth market

---

Polpharma Biologics' investigational biosimilar shows PK/PD comparability to inflammatory bowel disease blockbuster Entyvio®
Published: 2024-02-21 (Crawled : 08:00) - prnewswire.com
TAK | News | $13.36 0.91% 0.0% 1.5M |

Health Technology

| -9.85% | O: -0.88% H: 0.34% C: 0.34%
entyvio disease biosimilar

---

Albumin Market to Reach $9.9 billion, Globally, by 2032 at 6.2% CAGR: Allied Market Research
Published: 2024-02-15 (Crawled : 15:00) - prnewswire.com
FNCTF | News | $11.16 1.13% -20.84% 0 |

Communications

| -0.53% | O: 3.61% H: 0.0% C: -0.13%
TMO | News | $548.38 0.66% 0.86% 1.2M |

Health Technology

| 0.02% | O: -0.18% H: 1.09% C: 0.24%
TAK | News | $13.36 0.91% 0.0% 1.5M |

Health Technology

| -8.12% | O: -0.83% H: 0.38% C: 0.0%
reach research market

---

Protein Inhibitors Global Market Report 2024 - A $125 Billion Market in 2028, Registering Compound Annual Growth of 9%
Published: 2024-02-14 (Crawled : 02:00) - prnewswire.com
LZAGF | $541.144 -1.25% -19.1% 0 |

Health Technology

| 8.23% | O: 3.14% H: 1.92% C: 1.92%
GLAXF | News | $20.305 0.52% -14.18% 0 |

Health Technology

| -3.33% | O: -2.14% H: 0.0% C: -0.63%
SNYNF | News | $92.7 -2.18% 77 |

Health Technology

| -0.29% | O: -2.71% H: 0.0% C: 0.0%
AZNCF | News | $138.73 1.86% -4.19% 0 |

Health Technology

| 12.33% | O: 0.87% H: 0.21% C: -2.23%
LZAGY | $55.69 0.98% 0.02% 29K |

Professional, Scientific, and T...

| 12.17% | O: 4.07% H: 1.53% C: 1.45%
TMO | News | $548.38 0.66% 0.86% 1.2M |

Health Technology

| 1.82% | O: 0.56% H: 1.3% C: 1.22%
TAK | News | $13.36 0.91% 0.0% 1.5M |

Health Technology

| -6.83% | O: 0.42% H: 1.04% C: 0.97%
JNJ | News | $149.12 0.82% 0.3% 7.2M |

Health Technology

| -5.44% | O: -0.91% H: 0.0% C: 0.0%
GSK | News | $40.59 2.11% 0.1% 1.3K |

Health Technology

| -1.93% | O: 0.89% H: 0.41% C: 0.1%
LLY | News | $731.33 0.69% 0.36% 1.7M |

Health Technology

| -1.57% | O: 0.38% H: 2.44% C: 1.54%
BAX | $40.4 2.36% 0.0% 2.7M |

Health Technology

| 1.97% | O: 0.33% H: 0.63% C: -0.28%
ABBV | News | $167.89 0.89% 0.51% 3.6M |

Health Technology

| -3.77% | O: -0.73% H: 0.0% C: 0.0%
ABT | News | $107.07 -0.2% 0.18% 3.8M |

Health Technology

| -4.89% | O: -0.83% H: 0.66% C: 0.38%
SNY | News | $47.15 1.84% 1.75% 2M |

Health Technology

| 0.23% | O: -1.1% H: 0.0% C: 0.0%
GLPG | News | $29.07 -0.03% -0.14% 87 |

Health Technology

| -25.58% | O: -1.72% H: 1.8% C: 1.59%
BIIB | $194.11 -0.14% -0.15% 120 |

Health Technology

| -14.36% | O: 0.16% H: 0.43% C: -2.76%
AZN | News | $70.13 2.31% 2.24% 11K |

Health Technology

| 14.91% | O: 0.28% H: 0.93% C: 0.75%
AMGN | News | $271.91 1.11% 1.12% 560 |

Health Technology

| -6.39% | O: -0.21% H: 0.34% C: 0.07%
report global protein growth market

---

Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities
Published: 2024-02-13 (Crawled : 19:00) - biospace.com/
TAK | News | $13.36 0.91% 0.0% 1.5M |

Health Technology

| -6.64% | O: 0.14% H: 0.35% C: 0.07%
XNCR | $18.21 -0.93% -1.04% 510K |

Health Technology

| -11.21% | O: -3.56% H: 2.91% C: -3.34%
MOR | News | $17.96 -0.11% -0.06% 320K |

Health Technology

| 3.69% | O: -0.4% H: 0.23% C: -0.46%
MGNX | $15.41 -1.28% -1.3% 770K |

Health Technology

| -14.01% | O: -5.25% H: 2.94% C: 2.18%
INCY | $51.92 -0.82% -0.83% 1.8M |

Health Technology

| -10.24% | O: 3.8% H: 1.1% C: -1.17%
financial

---

FDA Approves Takeda’s EOHILIA (budesonide oral suspension), the First and Only Oral Treatment in the U.S. for Eosinophilic Esophagitis (EoE)
Published: 2024-02-12 (Crawled : 14:00) - biospace.com/
TAK | News | $13.36 0.91% 0.0% 1.5M |

Health Technology

| -6.18% | O: 0.07% H: 0.46% C: 0.42%
fda first treatment

---

Checkpoint Inhibitors Market Forecast Reveals Impressive Growth With Focus on Novel Therapies and Regional Expansion
Published: 2024-02-12 (Crawled : 23:00) - prnewswire.com
GLAXF | News | $20.305 0.52% -14.18% 0 |

Health Technology

| -1.11% | O: 3.52% H: 0.0% C: -1.18%
AZNCF | News | $138.73 1.86% -4.19% 0 |

Health Technology

| 14.97% | O: 0.06% H: 2.34% C: 2.29%
ALPMY | News | $9.53 0.32% -1.11% 0 |

Manufacturing

| -11.92% | O: 0.37% H: 0.74% C: 0.28%
TAK | News | $13.36 0.91% 0.0% 1.5M |

Health Technology

| -6.64% | O: 0.14% H: 0.35% C: 0.07%
NVS | News | $95.12 0.81% 5.43% 2.3M |

Health Technology

| -5.73% | O: -0.34% H: 0.23% C: -1.13%
JNJ | News | $149.12 0.82% 0.3% 7.2M |

Health Technology

| -4.78% | O: 0.7% H: 0.0% C: 0.0%
GSK | News | $40.59 2.11% 0.1% 1.3K |

Health Technology

| -1.17% | O: 1.22% H: 0.07% C: -0.43%
LLY | News | $731.33 0.69% 0.36% 1.7M |

Health Technology

| -0.8% | O: -0.96% H: 1.75% C: 1.75%
BMY | $49.14 0.43% 0.2% 6.4M |

Health Technology

| -1.23% | O: -0.18% H: 0.48% C: -1.91%
ABBV | News | $167.89 0.89% 0.51% 3.6M |

Health Technology

| -2.99% | O: 0.8% H: 0.0% C: 0.0%
ZLAB | $14.99 6.54% 6.01% 460K |

Health Technology

| -17.68% | O: -1.15% H: 1.03% C: -1.5%
VRTX | $399.92 1.43% 1.45% 1.1M |

Health Technology

| -5.01% | O: -0.28% H: 0.49% C: -0.32%
SNY | News | $47.15 1.84% 1.75% 2M |

Health Technology

| 0.16% | O: -0.06% H: 0.0% C: 0.0%
IPHA | $2.425 -0.62% -7.02% 9.5K |

Health Technology

| -6.2% | O: -3.1% H: 1.2% C: -0.8%
INCY | $51.92 -0.82% -0.83% 1.8M |

Health Technology

| -10.24% | O: 3.8% H: 1.1% C: -1.17%
BIIB | $194.11 -0.14% -0.15% 120 |

Health Technology

| -20.69% | O: -3.72% H: 0.58% C: -3.82%
AZN | News | $70.13 2.31% 2.24% 11K |

Health Technology

| 14.2% | O: -0.26% H: 0.73% C: -0.36%
ARGX | $368.75 2.37% 2.38% 2.5K |

Health Technology

| -6.1% | O: -2.3% H: 1.65% C: 0.83%
AMGN | News | $271.91 1.11% 1.12% 560 |

Health Technology

| -7.65% | O: 0.06% H: 0.31% C: -1.4%
expansion growth market

---

Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2023 Financial Results and Provides Financial Expectations for 2024
Published: 2024-02-07 (Crawled : 12:00) - prnewswire.com
TAK | News | $13.36 0.91% 0.0% 1.5M |

Health Technology

| -5.65% | O: 0.07% H: 0.42% C: 0.07%
NBIX | News M | $133.66 1.26% 1.12% 460K |

Health Technology

| -6.51% | O: -5.57% H: 6.04% C: 0.96%
financial results

---

Gainers vs Losers

73%

27%

Top 10 Gainers

AGBA | $2.5 100.0% 58.33% 200M |

Finance

EDBL | News | $6.26 66.49% 48.56% 270K |

NUWE | $0.334 29.96% 40.99% 2.5M |

Manufacturing

SILO | $1.99 0.71% 20.64% 1.8M |

Finance and Insurance

DPRO | News | $0.28 16.91% 16.26% 24K |

CANG | $1.34 -4.29% 14.93% 120K |

Technology Services

AZTR 4 | $0.195 13.85% 42K |

n/a

TOVX | News | $0.411 -1.01% 12.9% 230K |

Manufacturing

CISS | $1.3 11.11% 10.0% 42K |

n/a

SQNS | $0.504 -9.19% 9.25% 110K |

Electronic Technology

---

Your saved searches

---